• EMA unanimously recommends the approval of Hepizovac, vaccine against epizootic hemorrhagic disease.

• As a pioneering vaccine on the market, it is unique in its ability to prevent viremia caused by serotype 8 of the EHD virus in cattle.

• The vaccine is distributed in Spain and Portugal by Vetia Animal Health, Zendal Group’s dedicated subsidiary specializing in animal health.

O Porriño, March 18, 2025 – Spanish pharmaceutical group Zendal health  has just received a positive recommendation from the Committee for Medicinal Products for Veterinary Use (CVMP), part of the European Medicines Agency (EMA), for the granting of marketing authorization for HEPIZOVAC, a vaccine aimed at preventing epizootic hemorrhagic disease (EHD) in cattle, caused by serotype 8 of the virus.

This unanimous recommendation marks a fundamental milestone in the regulatory process for this vaccine, which was pioneering in the market and is  unique in its ability to prevent viremia caused by serotype 8 of the EHD virus in cattle.

A key advance in the fight against EHD

Epizootic hemorrhagic disease (EHD) virus, which affects domestic and wild ruminants, was first detected in southwestern Spain in November 2022. Given the rapid spread of the disease, the biopharmaceutical group prioritized the development of this vaccine. As a result, in July 2024 it received temporary authorization for use by the Spanish Agency for Medicines and Health Products (AEMPS) for the new vaccine, the first vaccine against this disease to be launched on the market.

Commitment to the livestock sector

Epizootic Hemorrhagic disease continues to spread across Spain, France, and other European countries, causing significant economic losses in cattle farms, both meat and dairy, due to direct mortality in animals, disease-related symptoms, and the after-effects in animals that have survived the viremic phase of the disease.

Hepizovac has demonstrated its efficacy for the active immunization of cattle against serotype 8 of the EHD virus, providing a key solution to protect cattle and mitigate the economic impact of the disease on Europe’s livestock sector.

Hepizovac is marketed in Spain and Portugal by Vetia Animal Health, a subsidiary of the Zendal group specializing in animal health.